Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma.

Chua V, Orloff M, Teh JL, Sugase T, Liao C, Purwin TJ, Lam BQ, Terai M, Ambrosini G, Carvajal RD, Schwartz G, Sato T, Aplin AE.

EMBO Mol Med. 2019 Jan 4. pii: e9081. doi: 10.15252/emmm.201809081. [Epub ahead of print]

2.

Correction: In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms.

Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE.

Cancer Discov. 2018 Dec;8(12):1654. doi: 10.1158/2159-8290.CD-18-1291. No abstract available.

PMID:
30510016
3.

ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma.

Capparelli C, Purwin TJ, Heilman SA, Chervoneva I, McCue PA, Berger AC, Davies MA, Gershenwald JE, Krepler C, Aplin AE.

Cancer Res. 2018 Oct 1;78(19):5680-5693. doi: 10.1158/0008-5472.CAN-18-1001. Epub 2018 Aug 16.

PMID:
30115691
4.

Publisher Correction: ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma.

Han S, Ren Y, He W, Liu H, Zhi Z, Zhu X, Yang T, Rong Y, Ma B, Purwin TJ, Ouyang Z, Li C, Wang X, Wang X, Yang H, Zheng Y, Aplin AE, Liu J, Shao Y.

Nat Commun. 2018 Apr 6;9(1):1404. doi: 10.1038/s41467-018-03710-1.

5.

In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms.

Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE.

Cancer Discov. 2018 May;8(5):568-581. doi: 10.1158/2159-8290.CD-17-0699. Epub 2018 Mar 1. Erratum in: Cancer Discov. 2018 Dec;8(12):1654.

PMID:
29496664
6.

ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma.

Han S, Ren Y, He W, Liu H, Zhi Z, Zhu X, Yang T, Rong Y, Ma B, Purwin TJ, Ouyang Z, Li C, Wang X, Wang X, Yang H, Zheng Y, Aplin AE, Liu J, Shao Y.

Nat Commun. 2018 Jan 2;9(1):28. doi: 10.1038/s41467-017-02354-x. Erratum in: Nat Commun. 2018 Apr 6;9(1):1404.

7.

Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo.

Hartsough EJ, Kugel CH 3rd, Vido MJ, Berger AC, Purwin TJ, Goldberg A, Davies MA, Schiewer MJ, Knudsen KE, Bollag G, Aplin AE.

Mol Cancer Ther. 2018 Jan;17(1):84-95. doi: 10.1158/1535-7163.MCT-17-0705. Epub 2017 Nov 13.

8.

Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma.

Cheng H, Chua V, Liao C, Purwin TJ, Terai M, Kageyama K, Davies MA, Sato T, Aplin AE.

Mol Cancer Ther. 2017 Mar;16(3):516-528. doi: 10.1158/1535-7163.MCT-16-0552. Epub 2017 Jan 30.

9.

An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.

Teh JL, Purwin TJ, Greenawalt EJ, Chervoneva I, Goldberg A, Davies MA, Aplin AE.

Cancer Res. 2016 Sep 15;76(18):5455-66. doi: 10.1158/0008-5472.CAN-15-3384. Epub 2016 Aug 3.

10.

MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma.

Vu HL, Rosenbaum S, Capparelli C, Purwin TJ, Davies MA, Berger AC, Aplin AE.

J Invest Dermatol. 2016 Feb;136(2):453-463. doi: 10.1016/j.jid.2015.11.012. Epub 2015 Nov 20.

11.

RAC1 P29S regulates PD-L1 expression in melanoma.

Vu HL, Rosenbaum S, Purwin TJ, Davies MA, Aplin AE.

Pigment Cell Melanoma Res. 2015 Sep;28(5):590-8. doi: 10.1111/pcmr.12392.

Supplemental Content

Loading ...
Support Center